Skip to main content
Top

Breast Cancer Research and Treatment

Issue 1/1997

Content (8 Articles)

Defining a role for c-Myc in breast tumorigenesis

Sharyl J. Nass, Robert B. Dickson

Antiestrogens: Mechanisms of action and resistance in breast cancer

Benita S. Katzenellenbogen, Monica M. Montano, Kirk Ekena, Mary E. Herman, Eileen M. McInerney

Histopathology grading in small brast cancers ≤ 10mm – results from an area with mammography screening

Lars-Gunnar Arnesson, Thomas Hatschek, Staffan Smeds, Otto Gröntoft

Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase

William E. Burak Jr., Anne L. Quinn, William B. Farrar, Robert W. Brueggemeier

Cytological evaluation of biological prognostic markers from primary breast carcinomas

A. Makris, D.C. Allred, T.J. Powles, M. Dowsett, I.N. Fernando, P.A. Trott, S.E. Ashley, M.G. Ormerod, J.C. Titley, C.K. Osborne

Trends in the incidence rate and risk factors for breast cancer in Japan

Chisato Nagata, Norito Kawakami, Hiroyuki Shimizu

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine